Filing Details

Accession Number:
0001209191-22-046489
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-17 19:41:42
Reporting Period:
2022-08-15
Accepted Time:
2022-08-17 19:41:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
906709 Nektar Therapeutics NKTR Pharmaceutical Preparations (2834) 943134940
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1789857 Jonathan Zalevsky C/O Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco CA 94158
Chief R&D Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-08-15 135,000 $0.00 411,399 No 4 A Direct
Common Stock Disposition 2022-08-16 10,560 $4.76 400,839 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Common Stock Acquisiton 2022-08-15 270,000 $0.00 270,000 $4.91
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
270,000 2030-08-14 No 4 A Direct
Footnotes
  1. Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted in connection with a retention program and are in lieu of the Issuer's usual end-of-year annual performance grants. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service.
  2. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  3. This transaction was executed in multiple trades at prices ranging from $4.67 to $4.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer.
  4. Stock options were granted in connection with a retention program and are in lieu of the Issuer's usual end-of-year annual performance grants.
  5. Stock options vest over three years from the date of grant in substantially equal monthly installments based on continued service.